Research Topics
| Gaetano MacrìSummaryAffiliation: University of Ferrara Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trialMarco Valgimigli
University of Ferrara, Cardiovascular Institute, Arcispedale S Anna Hospital, Ferrara, Italy
Circulation 125:2015-26. 2012..We evaluated the impact of up to 6 versus 24 months of dual-antiplatelet therapy in a broad all-comers patient population receiving a balanced proportion of Food and Drug Administration-approved drug-eluting or bare-metal stents...- Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOppinMarco Valgimigli
Chair of Cardiology, University of Ferrara, Ferrara, Italy
JACC Cardiovasc Interv 5:268-77. 2012.... - Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registryMarco Valgimigli
Institute of Cardiology, University of Ferrara, Ferrara, Italy
JACC Cardiovasc Interv 5:23-35. 2012..This study sought to assess whether transradial intervention, by minimizing access-site bleeding and vascular events, improves outcomes in patients with ST-segment elevation myocardial infarction compared with the transfemoral approach... - Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol designMarco Valgimigli
University of Ferrara, Cardiovascular Institute, Arcispedale S Anna Hospital, Corso Giovecca 203, 44100 Ferrara, Italy
Cardiovasc Drugs Ther 22:313-20. 2008.... - Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients ShoMarco Valgimigli
Cardiovascular Institute, University of Ferrara, S Anna Hospital, Corso Giovecca 203, Ferrara, Italy
Circulation 119:3215-22. 2009..Whether this reflects suboptimal platelet inhibition per se, which might benefit from more potent antiplatelet agents such as tirofiban, is unknown... - Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trialsMarco Valgimigli
Cardiovascular Institute, Azienda Opedaliera Universitaria di Ferrara, Corso Giovecca 203, Ferrara 44100, Italy
Eur Heart J 31:35-49. 2010..To perform a thorough and updated systematic review of randomized clinical trials comparing tirofiban vs. placebo or vs. abciximab... - Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents?Marco Valgimigli
Department of Cardiology, University of Ferrara, Cardiovascular Institute, Arcispedale S Anna, Italy
J Cardiovasc Med (Hagerstown) 10:S17-26. 2009..In conclusion, stent choice in primary PCI cannot be standardized for all patients and appears to be influenced by various factors that need to be considered to provide better revascularization in terms of both efficacy and safety... - Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stentingM Valgimigli
Institute of Cardiology, University of Ferrara, Ferrara, Italy
J Thromb Haemost 8:1903-11. 2010..The concomitant administration of high loading dose clopidogrel, by bridging with abciximab bolus, may sustain suppression of platelet activity over time... - Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment Marco Valgimigli
Cardiology Department, University of Ferrara, Ferrara, Italy
Am Heart J 160:804-11. 2010.... - Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacyMarco Valgimigli
University of Ferrara, Italy and Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago BS, Italy
Am Heart J 160:S36-41. 2010..Selection of agents and their combination, dose optimization, and a customized approach based on genotype or assessment of on-treatment phenotype are discussed in the context of available evidence... - Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and SMarco Valgimigli
Cardiovascular Institute, University of Ferrara, Ferrara, Italy
JACC Cardiovasc Interv 4:51-62. 2011..These studies sought to investigate the impact on mortality of coronary flow after passage of the wire through the culprit vessel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing mechanical reperfusion... - Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trialMarco Valgimigli
Cardiovascular Institute, University of Ferrara, Ferrara, Italy
JAMA 299:1788-99. 2008..Similarly, the use of drug-eluting stents in this patient population is currently discouraged because of conflicting results on efficacy reported in randomized trials and safety concerns reported by registries... 
Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY studyMarco Valgimigli
Institute of Cardiology, University of Ferrara, Ferrara, Italy
J Am Coll Cardiol 50:138-45. 2007..Moreover, the distribution of clinical events in relation to thienopyridine discontinuation was thoroughly investigated...- Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarctionMarco Valgimigli
University of Ferrara, Ferrara, Italy
J Am Coll Cardiol 43:2000-8. 2004.... - High-dose bolus tirofiban and sirolimus eluting stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study--protocol design and demography of the first 100 patientsMarco Valgimigli
University of Ferrara, Cardiovascular Institute, Arcispedale S Anna Hospital, C rso Giovecca 203, 44100 Ferrara, Italy
Cardiovasc Drugs Ther 18:225-30. 2004..With current European list prices, the use of tirofiban instead of abciximab would save enough money to absorb the difference between SES and BMS... - The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE TrialMarco Valgimigli
Department of Cardiology, University of Ferrara, Ferrara, Italy
J Am Coll Cardiol 44:14-9. 2004..We sought to determine the safety and efficacy of high-dose bolus (HDB) tirofiban in high-risk patients undergoing percutaneous coronary intervention (PCI)... - CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failureMarco Valgimigli
University of Ferrara and Cardiovascular Research Center, Salvatore Maugeri Foundation, IRCCS, Gussago, Italy
Circulation 110:1209-12. 2004..We investigated the pattern of CD34(+) cells and EPC mobilization during HF and their correlation with the severity and origin of the disease... - Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) studyMarco Valgimigli
Chair of Cardiology, University of Ferrara Cardiovascular Institute, Arcispedale S Anna, C rso Giovecca 203, 44100 Ferrara, Italy
Circulation 111:863-70. 2005..Despite the recognition that several TNF family cytokines are elevated during myocardial infarction, their role in predicting subsequent prognosis in these setting remains poorly understood... - Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profileMarco Valgimigli
Section of Cardiology, University of Ferrara and Cardiovascular Research Centre, Arcispedale S Anna C rso Giovecca 203, 44100 Ferrara, Italy
Eur Heart J 26:1838-45. 2005..We sought to assess the safety and feasibility of granulocyte-colony stimulating factor (G-CSF) administration in humans to enhance SC mobilization and left ventricle (LV) injury repair during myocardial infarction (MI)... - Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trialMarco Valgimigli
Chair of Cardiology, University of Ferrara, Cardiovascular Institute, Arcispedale S Anna, Italy
JAMA 293:2109-17. 2005..At current European list prices, the use of tirofiban instead of abciximab would absorb the difference in cost between stenting with sirolimus-eluting vs bare-metal stents... - [Markers of coronary damage. From diagnosis to prognosis]Marco Valgimigli
Cattedra di Cardiologia, Universita, Ferrara
Recenti Prog Med 96:566-72. 2005..Several prospective epidemiological studies have documented an association between inflammatory markers and cardiovascular disease and their role in primary and secondary prevention and as predictor of mortality... - The heart of coronary arteriesMarco Valgimigli
Institute of Cardiology, University of Ferrara, C.rso Giovecca 203, 44100 Ferrara, Italy
Eur Heart J 28:2063. 2007 - Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGMarco Valgimigli
Cardiology, University of Ferrara, Ferrara, Italy
Am Heart J 154:39-45. 2007..Similarly, whether tirofiban administered at high-bolus dose (HBD) followed by standard infusion is a valuable alternative to abciximab in the setting of ST-segment elevation myocardial infarction remains uncertain... - Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stressMarco Valgimigli
Department of Cardiology, University of Ferrara c o Arcispedale S Anna, Corso Giovecca 203, 44100 Ferrara, Italy
Arch Biochem Biophys 420:255-61. 2003..Thus, oxidative stress, irrespective of atherosclerotic disease stages, seems to represent a key phenomenon in vascular disease progression and possible prevention... - Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stentingGianluca Campo
Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
Clin Appl Thromb Hemost 16:591-3. 2010....